UNDERWRITING AGREEMENT between BRIACELL THERAPEUTICS CORP. and THINKEQUITY LLC as Representative of the Several Underwriters BRIACELL THERAPEUTICS CORP.Underwriting Agreement • December 13th, 2024 • BriaCell Therapeutics Corp. • Pharmaceutical preparations • New York
The undersigned, BriaCell Therapeutics Corp., a corporation formed under the laws of the Province of British Columbia (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of BriaCell Therapeutics Corp. (the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
GENELUX CORPORATION 6,875,000 Shares of Common Stock and Warrants to Purchase 6,875,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 24th, 2024 • GENELUX Corp • Pharmaceutical preparations • New York
Genelux Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of (i) 6,875,000 shares (the “Firm Shares”) of its common stock, par value $0.001 per share (the “Common Stock”) and (ii) warrants (the “Firm Warrants,” together with the Firm Shares, the “Firm Securities”) to purchase up to 6,875,000 shares of Common Stock in the form set forth in Exhibit A hereto . The Company also proposes to issue and sell to the several Underwriters up to (i) an additional 1,031,250 shares (the “Additional Shares,”) of Common Stock and (ii) additional warrants to purchase an aggregate of 1,031,250 shares of Common Stock (the “Additional Warrants,” and collectively with the Firm Securities and Additional Shares, the “Securities”) at the option of the Underwriters as provided in Section 2
INTERPACE DIAGNOSTICS GROUP, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • June 21st, 2017 • Interpace Diagnostics Group, Inc. • Surgical & medical instruments & apparatus • New York
Interpace Diagnostics Group, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of: (i) 9,900,000 shares (“Firm Shares”) of the Company’s common stock, $0.01 par value per share (“Shares”), (ii) warrants to purchase 12,500,000 Shares at an exercise price equal to $1.25 per share (“Base Warrants”), and (iii) warrants to purchase 2,600,000 Shares at an exercise price equal to $0.01 per share (“Pre-Funded Warrants”) to the several underwriters (such underwriters, for whom Maxim Group LLC (“Maxim” or the “Representative”) is acting as representative, the “Underwriters” and each an “Underwriter”). Each Firm Share shall be sold together with a Base Warrant to purchase one Share; or, alternatively, each Pre-Funded Warrant shall be sold, in lieu of a Share, together with a Base Warrant to purchase one Share. Such Base Warrants and Pre-Funded Warrants are hereinafter collectively called the “Firm Warrants,” a